Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Capital Expenditures (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Capital Expenditures data on record, last reported at $454000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 52.71% year-over-year to $454000.0; the TTM value through Dec 2025 reached $1.9 million, up 19.04%, while the annual FY2025 figure was $1.9 million, 19.04% up from the prior year.
  • Capital Expenditures reached $454000.0 in Q4 2025 per RVMD's latest filing, up from -$9.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $7.9 million in Q2 2025 and bottomed at -$9.3 million in Q3 2025.
  • Average Capital Expenditures over 5 years is $956400.0, with a median of $1.2 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 9572.97% in 2021, then tumbled 465.86% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $1.2 million in 2021, then crashed by 212.85% to -$1.3 million in 2022, then skyrocketed by 273.56% to $2.3 million in 2023, then plummeted by 58.57% to $960000.0 in 2024, then plummeted by 52.71% to $454000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $454000.0 in Q4 2025, -$9.3 million in Q3 2025, and $7.9 million in Q2 2025.